Cargando…
Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672751/ https://www.ncbi.nlm.nih.gov/pubmed/35918963 http://dx.doi.org/10.4103/ijo.IJO_753_22 |
| _version_ | 1784832808635596800 |
|---|---|
| author | Gopal, Lingam |
| author_facet | Gopal, Lingam |
| author_sort | Gopal, Lingam |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9672751 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96727512022-11-19 Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration Gopal, Lingam Indian J Ophthalmol Commentary Wolters Kluwer - Medknow 2022-08 /pmc/articles/PMC9672751/ /pubmed/35918963 http://dx.doi.org/10.4103/ijo.IJO_753_22 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Commentary Gopal, Lingam Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title | Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title_full | Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title_fullStr | Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title_full_unstemmed | Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title_short | Commentary:A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| title_sort | commentary:a prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672751/ https://www.ncbi.nlm.nih.gov/pubmed/35918963 http://dx.doi.org/10.4103/ijo.IJO_753_22 |
| work_keys_str_mv | AT gopallingam commentaryaprospectiverandomizedparallelgroupdoubleblindmulticenterstudytocomparetheefficacysafetyandimmunogenicityoflupinsranibizumabwithlucentisinpatientswithneovascularagerelatedmaculardegeneration |